Are you an enthusiastic molecular biologist with a passion for developing new technological frontiers in nucleic acid therapies? Do you want to join a vibrant, creative team that makes a difference in patients’ lives? If so – look no further!
In a nut-shell
Eleven Tx is seeking two passionate and innovative senior scientists to join our efforts in developing a new generation of RNA-based therapies. The successful candidates will utilise state-of-the-art techniques aimed to tackle today’s challenges in the delivery, durability, and long-lasting effects of life-saving RNA therapies. The successful candidates are creative and well-rounded molecular biologists with a proven track record of high impact publications and demonstrated skills in nucleic acid R&D.
As a senior scientist you will contribute to the design and development of new massively-parallel combinatorial platforms that span the gamut, from nucleic acid synthesis to functional characterisation in a range of biological systems. You will identify and implement novel tools in RNA and cell biology, propose experimental designs and strategies, and work closely with other team members to implement and troubleshoot your systems. Eleven fosters an interdisciplinary environment, where you will collaborate with the Artificial Intelligence team and further develop new areas of research aimed to provide safe, effective and durable therapeutics.
Essential for the role
About Eleven Therapeutics
Eleven Tx brings Artificial Intelligence into the heart of RNAi to develop the future of RNA interference therapeutics. We develop proprietary platforms, harnessing massively parallel functional assays, to decipher the programmable nature of nucleic acids and unlock the rules of hyper-potency, durability and on-target delivery of life-saving therapeutics. Eleven Tx was founded, and is led by a multidisciplinary team of world-class scientists, including Prof. Greg Hannon (Director of Cancer Research UK Cambridge Institute), Prof. Yaniv Erlich (ex-Columbia University Prof. of Computer Science, MIT/Whitehead Institute Fellow), Shaul Ilan (serial entrepreneur with a track-record of success in Gene Editing solutions), and Dr. Iris Grossman (ex-VP Head of Early-Stage Clinical Development at Teva Pharmaceuticals, Chief Scientific Officer of several Biotech). Eleven Tx is backed by leading VCs and was awarded highly competitive multi-million-dollar non-dilutive grants.
Wish to apply?
Please click the apply button to email a copy of your CV and a short description of your motivation.
Should we receive a high volume of interest, we may close applications for these vacancies before the deadline, so you are advised to express your interest as soon as possible.
|Placed On:||25th November 2021|
|Expires:||24th January 2022|
Type / Role: